tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

VYNE Stock Latest News

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
Press ReleasesVYNE Reports First Quarter 2024 Financial Results and Provides Business Update
19d ago
VYNE
VYNE Therapeutics expects cash to fund operations through 2025
PremiumThe Fly
VYNE Therapeutics expects cash to fund operations through 2025
19d ago
VYNE
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year
PremiumThe Fly
VYNE Therapeutics reports Q1 EPS (15c) vs. ($1.74) last year
19d ago
VYNE
VYNE Therapeutics announces FDA clearance of IND application for VYN202
PremiumThe Fly
VYNE Therapeutics announces FDA clearance of IND application for VYN202
22d ago
VYNE
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
PremiumPress Releases
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting
27d ago
VYNE
Vyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
PremiumCompany AnnouncementsVyne Therapeutics Inc’s New Natural and Human Disruptions Risk – A Cause for Worry?
3M ago
VYNE
VYNE Therapeutics files $250M mixed securities shelf
PremiumThe Fly
VYNE Therapeutics files $250M mixed securities shelf
3M ago
VYNE
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
PremiumPress Releases
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
3M ago
VYNE
VYNE Therapeutics expects cash to fund operations through 2025
PremiumThe Fly
VYNE Therapeutics expects cash to fund operations through 2025
3M ago
VYNE
VYNE Therapeutics reports Q4 EPS (20c) vs. ($2.60) last year
PremiumThe Fly
VYNE Therapeutics reports Q4 EPS (20c) vs. ($2.60) last year
3M ago
VYNE
VYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
VYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
VYNE
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
PremiumPress Releases
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
3M ago
VYNE
VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
PremiumPress ReleasesVYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
5M ago
VYNE
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
PremiumThe Fly
VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
5M ago
VYNE
VYNE Therapeutics appoints Borowski to board of directors
PremiumThe Fly
VYNE Therapeutics appoints Borowski to board of directors
5M ago
VYNE
VYNE Therapeutics files to sell 39.27M shares of common stock for holders
PremiumThe Fly
VYNE Therapeutics files to sell 39.27M shares of common stock for holders
7M ago
VYNE
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
PremiumPress Releases
VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7M ago
VYNE
VYNE Therapeutics expects cash to fund operations through 2025
PremiumThe Fly
VYNE Therapeutics expects cash to fund operations through 2025
7M ago
VYNE
VYNE Therapeutics reports Q3 EPS ($201) vs. ($2.94) last year
PremiumThe Fly
VYNE Therapeutics reports Q3 EPS ($201) vs. ($2.94) last year
7M ago
VYNE
VYNE Therapeutics to host virtual research and development day
PremiumThe FlyVYNE Therapeutics to host virtual research and development day
7M ago
VYNE
VYNE Therapeutics to host virtual research and development day
PremiumThe Fly
VYNE Therapeutics to host virtual research and development day
7M ago
VYNE
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
PremiumPress Releases
VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million
7M ago
VYNE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >